Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool
Psychopharmacology Bulletin · 2026
DOI: 10.64719/pb.15423 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Roberto Lozano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lozano, PhD, PharmD., Department of Pharmacy, University Clinical Hospital "Lozano Blesa", Zaragoza, Spain. Hauptthemen laut MEDLINE: Olanzapine, Clozapine, Antipsychotic Agents, Obesity. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Clozapine and olanzapine are associated with clinically relevant weight gain and metabolic risk.
Objective
To compare the risk of obesity (BMI ⩾ 30) between clozapine and olanzapine and to develop a parsimonious prediction model with performance and clinical-utility evaluation.
Methods
We fit a multivariable logistic regression on complete cases using index drug, daily dose, prolactin (PRL), cortisol, free thyroxine (FT4), and HDL. Discrimination (AUC), probability accuracy (Brier score), calibration (intercept/slope and deciles), and decision-curve analysis (DCA) were reported.
Results
In the classification cohort, obesity counts were equal for clozapine (9/19) and olanzapine (9/19). The model achieved strong internal discrimination (AUC 0.869) with good calibration (slope 1.00; intercept −0.00) and Brier 0.123. DCA indicated net benefit at practical thresholds (∼5–15%), supporting low-harm preventive actions.
Conclusions
Drug-related risk can be individualized with a lean model using routine variables. External validation and unit harmonization—especially for HDL—are recommended before broad deployment. Psychopharmacology Bulletin. 2026;56(1):71–81.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lozano, PhD, PharmD., Department of Pharmacy, University Clinical Hospital "Lozano Blesa", Zaragoza, Spain.
- Bona, Unit for the Rational Use of Medicines, Aragon Health Service, Zaragoza, Spain.
Zitieren
APA
Lozano, R., & Bona, C. (2026). Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.15423
Vancouver
Lozano R, Bona C. Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.15423
BibTeX
@article{Lozano2026,
author = {Lozano, Roberto and Bona, Carina},
title = {Risk of Obesity in Patients Treated with Clozapine or Olanzapine: A Simple, Clinically Useful Prediction Tool},
journal = {Psychopharmacology Bulletin},
year = {2026},
doi = {10.64719/pb.15423}
}
EUVIMED